Biosimilars A Driving Force Behind Korean Pharma Exports
This article was originally published in PharmAsia News
Executive Summary
Remsima/Inflectra's rapid penetration into global biosimilar markets is helping Celltrion to grow into a global biologics powerhouse and also boosting South Korea's pharma exports. The country has logged a biologics trade surplus for the first time in years, due mainly to a surge in exports of biosimilar infliximab, and trend only set to continue with more approvals and launches on the horizon.
You may also be interested in...
Remsima Stars In Orion Pharma’s First Half
Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.
Remsima Stars In Orion Pharma’s First Half
Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.